Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 5, 2007

Hypertension. 2007
Published online before print March 5, 2007, doi: 10.1161/01.HYP.0000260471.16113.d8
A more recent version of this article appeared on April 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
49/4/878    most recent
01.HYP.0000260471.16113.d8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giannarelli, C.
Right arrow Articles by Salvetti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannarelli, C.
Right arrow Articles by Salvetti, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Other hypertension
Right arrow Fibrinolysis
Right arrow Endothelium/vascular type/nitric oxide

Submitted on September 12, 2006
Revised on September 25, 2006

Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients

Chiara Giannarelli*; Ferdinando De Negri; Agostino Virdis; Lorenzo Ghiadoni; Alessandro Cipriano; Armando Magagna; Stefano Taddei; and Antonio Salvetti

From the Department of Internal Medicine, University of Pisa, Pisa, Italy.

* To whom correspondence should be addressed. E-mail: c.giannarelli{at}int.med.unipi.it.

Abstract--We evaluated the possible role of NO in modulating tissue plasminogen activator (t-PA) release in the forearm microcirculation of normotensive subjects and hypertensive patients. Essential hypertensive patients are characterized by endothelial dysfunction because of a reduced NO availability and also show an impaired t-PA release. In healthy volunteers and essential hypertensive patients, we studied local t-PA release and forearm blood flow changes (strain-gauge plethysmography) induced by intrabrachial administration of acetylcholine (0.45 and 1.5 µg/100 mL/min) and of sodium nitroprusside (0.5 and 1.0 µg/100 mL/min), an endothelium-dependent and -independent agonist, respectively. Acetylcholine was also repeated in the presence of intra-arterial infusion of the NO synthase inhibitor NG-monomethyl-L-arginine (100 µg/100 mL/min). In normotensive subjects, vasodilation to acetylcholine was blunted by NG-monomethyl-L-arginine. In these subjects, acetylcholine infusion induced a significant, dose-dependent increase in net forearm t-PA release. NG-monomethyl-L-arginine significantly reduced basal t-PA release, as well as acetylcholine-induced t-PA release. In essential hypertensive patients, vasodilation to acetylcholine was reduced as compared with controls and resistant to NG-monomethyl-L-arginine. In contrast to what was observed in healthy control subjects, in hypertensive patients, acetylcholine had no effect on t-PA release. Similarly, NG-monomethyl-L-arginine failed to modify either the tonic or the agonist-induced t-PA release. Both tonic and agonist-induced release of NO are directly involved in t-PA release by endothelial cells. Essential hypertension, characterized by a reduction in tonic and stimulated NO availability, is also associated with impaired capacity of t-PA release, suggesting a major role of impaired NO availability in worsening both vasodilation and t-PA release.


Key words: endothelium • tissue plasminogen activator • nitric oxide • acetylcholine • microcirculation • hypertension • essential




This article has been cited by other articles:


Home page
CirculationHome page
C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei
Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Circulation, March 31, 2009; 119(12): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway
Hypertension, August 1, 2008; 52(2): 314 - 321.
[Abstract] [Full Text] [PDF]